4//SEC Filing
Fox Christine 4
Accession 0000950170-25-034687
CIK 0000818686other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:19 PM ET
Size
11.6 KB
Accession
0000950170-25-034687
Insider Transaction Report
Form 4
Fox Christine
EVP, Head of U.S. Commercial
Transactions
- Exercise/Conversion
Ordinary Shares
2025-03-04+20,461→ 64,565 total - Sale
Ordinary Shares
2025-03-04$15.73/sh−4,034$63,473→ 60,531 total - Sale
Ordinary Shares
2025-03-05$15.91/sh−2,147$34,166→ 58,384 total - Exercise/Conversion
Restricted Share Units
2025-03-04−20,461→ 61,384 total→ Ordinary Shares (20,461 underlying)
Footnotes (7)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2024.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F7]Restricted share units were granted on March 4, 2024, with 20,461 vested on March 4, 2025, 20,461 vesting on each of March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001998173
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:19 PM ET
- Size
- 11.6 KB